A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals.
暂无分享,去创建一个
[1] B. Chumpitazi,et al. Pediatric gastrointestinal motility disorders: challenges and a clinical update. , 2008, Gastroenterology & hepatology.
[2] O. Dulac,et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.
[3] Shyam Sundar,et al. Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.
[4] M. Benninga,et al. Pharmacokinetics of a Single Oral Dose of Baclofen in Pediatric Patients With Gastroesophageal Reflux Disease , 2003, Therapeutic drug monitoring.
[5] W. Rosenfeld,et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. , 1999, Pediatric neurology.
[6] Carol Taketomo,et al. Pediatric Dosage Handbook: Including Neonatal Dosing, Drug Administration, & Extemporaneous Preparations , 2009 .
[7] Y. Vandenplas,et al. Diagnosis and treatment of gastro‐oesophageal reflux disease in infants and children , 2000, Annals of medicine.
[8] Denise Thomson,et al. Standard 6: Age Groups for Pediatric Trials , 2012, Pediatrics.
[9] P. Levisohn. Safety and Tolerability of Topiramate in Children , 2000, Journal of child neurology.
[10] M. Kukulka,et al. Age-Dependent Pharmacokinetics of Lansoprazole in Neonates and Infants , 2008, Paediatric drugs.
[11] Siv Jönsson,et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms , 2008, Pharmacogenetics and genomics.
[12] Marsha G Raanan,et al. Safety and Pharmacodynamics of Lansoprazole in Patients with Gastroesophageal Reflux Disease Aged <1 Year , 2008, Paediatric drugs.
[13] M. Thomson,et al. Intestinal Metabolism and Transport of Drugs in Children: The Effects of Age and Disease , 2008, Journal of pediatric gastroenterology and nutrition.
[14] R. Dimmitt,et al. Baclofen for the Treatment of Pediatric GERD , 2013, Journal of pediatric gastroenterology and nutrition.
[15] G. Amidon,et al. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. , 2014, Molecular pharmaceutics.
[16] J. Asconapé. The selection of antiepileptic drugs for the treatment of epilepsy in children and adults. , 2010, Neurologic clinics.
[17] Arik Dahan,et al. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[18] G. Crippen,et al. Purely in silico BCS classification: science based quality standards for the world's drugs. , 2013, Molecular pharmaceutics.
[19] I. Kanfer,et al. Pharmacokinetics of Oral Decongestants , 1993, Pharmacotherapy.
[20] G. Amidon,et al. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. , 2009, Molecular pharmaceutics.
[21] O. Dulac,et al. Stiripentol: Efficacy and Tolerability in Children with Epilepsy , 1999, Epilepsia.
[22] H. Dammann,et al. Clinical characteristics of roxatidine acetate: a review. , 1988, Scandinavian journal of gastroenterology. Supplement.
[23] Lawrence X. Yu,et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. , 2010, Molecular pharmaceutics.
[24] R. Egan,et al. Comparative Oral and Topical Decongestant Effects of Phenylpropanolamine and d-Pseudoephedrine , 2001, American journal of rhinology.
[25] I. Tamai,et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. , 2011, Journal of pharmaceutical sciences.
[26] J. Hardcastle,et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.
[27] J. W. Poole,et al. Serum concentrations of ampicillin in newborn infants after oral administration. , 1973, Pediatrics.
[28] J. Pácha. Development of intestinal transport function in mammals. , 2000, Physiological reviews.
[29] G. Runge,et al. Investigations on the bacterial flora, pH, and sugar content in the intestinal tract of infants. , 1952, The Journal of pediatrics.
[30] G. Koren,et al. Neonatal and pediatric clinical pharmacology. , 2012, Pediatric clinics of North America.
[31] E. Thiele,et al. Efficacy and safety of rufinamide in pediatric epilepsy , 2013, Therapeutic advances in neurological disorders.
[32] D. Wall,et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation , 2009, Pediatric blood & cancer.
[33] A. Dahan,et al. Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations , 2013, PloS one.
[34] G. Ecker,et al. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.
[35] L. Lázaro,et al. Fluoxetine pharmacogenetics in child and adult populations , 2012, European Child & Adolescent Psychiatry.
[36] M. Danhof,et al. What is the right dose for children? , 2010, British journal of clinical pharmacology.
[37] A. Dahan,et al. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[38] W. Crom. Pharmacokinetics in the child. , 1994, Environmental health perspectives.
[39] M. Armand,et al. Enzyme replacement therapy for pancreatic insufficiency: present and future , 2011, Clinical and experimental gastroenterology.
[40] S. D. de Wildt,et al. Ontogeny of oral drug absorption processes in children , 2012, Expert opinion on drug metabolism & toxicology.
[41] S. Abdel‐Rahman,et al. Pediatric pharmacokinetics: human development and drug disposition. , 2012, Pediatric clinics of North America.
[42] A. Dahan,et al. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[43] Stewart Cf,et al. Effect of maturation on drug disposition in pediatric patients. , 1987 .
[44] G. Kearns,et al. Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine , 2004, Journal of pediatric gastroenterology and nutrition.
[45] J. Boos,et al. Randomized clinical trials in children--ethical and methodological issues. , 2010, Current pharmaceutical design.
[46] N. Huang,et al. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. , 1953, The Journal of pediatrics.
[47] E. Thiele,et al. New drugs for pediatric epilepsy. , 2010, Seminars in pediatric neurology.
[48] P. Lundborg,et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. , 2000, The Journal of pediatrics.
[49] H Lennernäs,et al. Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.
[50] G. Amidon,et al. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[51] T. Glauser,et al. Topiramate Pharmacokinetics in Infants , 1999, Epilepsia.
[52] G. Amidon,et al. Multiple Efflux Pumps Are Involved in the Transepithelial Transport of Colchicine: Combined Effect of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Leads to Decreased Intestinal Absorption Throughout the Entire Small Intestine , 2009, Drug Metabolism and Disposition.
[53] S. Sundar,et al. Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial , 2013, Tropical medicine & international health : TM & IH.
[54] R. Guerrini,et al. Topiramate in the Treatment of Epilepsy - A Review , 2006 .
[55] R. D. Brown,et al. Antimicrobial Therapy in Neonates, Infants and Children , 1989, Clinical pharmacokinetics.
[56] Gordon L Amidon,et al. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. , 2010, Journal of pharmaceutical sciences.
[57] S. Hertz,et al. Regulatory review of acetaminophen clinical pharmacology in young pediatric patients. , 2012, Journal of pharmaceutical sciences.
[58] C. Faure,et al. Pharmacokinetics of Proton Pump Inhibitors in Children , 2005, Clinical pharmacokinetics.
[59] Viktoriya Ioffe-Dahan,et al. The Twofold Advantage of the Amorphous Form as an Oral Drug Delivery Practice for Lipophilic Compounds: Increased Apparent Solubility and Drug Flux Through the Intestinal Membrane , 2012, The AAPS Journal.
[60] A. Matas,et al. Infant Human Pancreas: A Potential Source of Islet Tissue for Transplantation , 1976, Diabetes.
[61] J. Fallingborg,et al. Intraluminal pH of the human gastrointestinal tract. , 1999, Danish medical bulletin.
[62] G. Kearns,et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny , 2003, Clinical pharmacology and therapeutics.
[63] R. de Groot,et al. Pharmacokinetics of Nelfinavir in Children: Influencing Factors and dose Implications , 2002, Antiviral therapy.
[64] Stephen S. Hwang,et al. In Vitro and In Vivo Evaluation of a Once‐Daily Controlled‐Release Pseudoephedrine Product , 1995, Journal of clinical pharmacology.
[65] A. Dahan,et al. The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs , 2012, The AAPS Journal.
[66] L. A. Christensen,et al. Measurement of Gastrointestinal pH and Regional Transit Times in Normal Children , 1990, Journal of pediatric gastroenterology and nutrition.
[67] R. Guerrini,et al. A Pharmacokinetic Study and Correlation with Clinical Response of Rufinamide in Infants with Epileptic Encephalopathies , 2013, Pharmacology.
[68] G. Amidon,et al. The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport , 2009, The AAPS Journal.
[69] Arik Dahan,et al. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. , 2012, Molecular pharmaceutics.
[70] G. Kearns,et al. The Bioequivalence of Nizatidine (Axid®) in Two Extemporaneously and One Commercially Prepared Oral Liquid Formulations Compared with Capsule , 2003, Journal of clinical pharmacology.
[71] R. V. van Lingen,et al. Acetaminophen Developmental Pharmacokinetics in Premature Neonates and Infants: A Pooled Population Analysis , 2002, Anesthesiology.
[72] S. Urien,et al. Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children , 2006, Antimicrobial Agents and Chemotherapy.
[73] Hans Lennernäs,et al. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. , 2014, Molecular pharmaceutics.
[74] P D Griffiths,et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] C. Brandt,et al. Serum Concentrations of Rufinamide in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication , 2011, Therapeutic drug monitoring.
[76] Y. Vandenplas. Management of paediatric GERD , 2014, Nature Reviews Gastroenterology &Hepatology.
[77] Arik Dahan,et al. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[78] G. Amidon,et al. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. , 2012, Molecular pharmaceutics.
[79] R. Baldassano,et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[80] G. Anderson,et al. Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach , 2009, Pharmacotherapy.
[81] F. Dimario,et al. Childhood Head Tremor , 2000, Journal of child neurology.
[82] Warren Gh,et al. Serum concentrations of sodium nafcillin in infants during the perinatal period. , 1965 .
[83] S. Yum,et al. Efficacy and Tolerability of Topiramate in Children Younger Than 2 Years Old , 2005, Journal of child neurology.
[84] G. Maira,et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients , 2003, Cancer Chemotherapy and Pharmacology.
[85] R. Riccardi,et al. Role of temozolomide in pediatric brain tumors , 2006, Child's Nervous System.
[86] Imke H. Bartelink,et al. Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations , 2006, Clinical pharmacokinetics.
[87] G. Brown,et al. Duodenal bile acids in infancy. , 1975, Archives of disease in childhood.
[88] S. Mahant,et al. Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease , 2013, Pharmacotherapy.
[89] M. Gersten,et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] L. Nguyen,et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. , 2010, Blood.
[91] A. Hoffman,et al. Use of a Dynamic in Vitro Lipolysis Model to Rationalize Oral Formulation Development for Poor Water Soluble Drugs: Correlation with in Vivo Data and the Relationship to Intra-Enterocyte Processes in Rats , 2006, Pharmaceutical Research.
[92] V. Purohit. Biopharmaceutic Planning in Pediatric Drug Development , 2012, The AAPS Journal.
[93] G. Koren,et al. Back to basics: understanding drugs in children: pharmacokinetic maturation. , 2005, Pediatrics in review.
[94] R. Guerrini,et al. Topiramate and its clinical applications in epilepsy , 2006, Expert opinion on pharmacotherapy.
[95] J. Panetta,et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors , 2003, Cancer Chemotherapy and Pharmacology.
[96] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[97] G. Amidon,et al. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. , 2012, Clinical therapeutics.
[98] J. Beijnen,et al. Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.
[99] M. Baker. Antidotes for nerve agent poisoning: should we differentiate children from adults? , 2007, Current opinion in pediatrics.
[100] Brady T. West,et al. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[101] R. Gilbert,et al. Cisapride treatment for gastro-oesophageal reflux in children. , 2010, The Cochrane database of systematic reviews.
[102] Takeyuki Sato,et al. Population Pharmacokinetics of Oral Busulfan in Young Japanese Children Before Hematopoietic Stem Cell Transplantation , 2008, Therapeutic drug monitoring.
[103] L. Michaud,et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis , 2001, Alimentary pharmacology & therapeutics.
[104] S. Cremers,et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. , 2002, British journal of clinical pharmacology.
[105] R. Strickley,et al. Pediatric drugs--a review of commercially available oral formulations. , 2008, Journal of pharmaceutical sciences.
[106] Mirjam N Trame,et al. Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children , 2011, Clinical Cancer Research.
[107] G. Amidon,et al. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. , 2010, International journal of pharmaceutics.
[108] E. Garofalo,et al. Clinical development of antiepileptic drugs for children , 2011, Neurotherapeutics.
[109] W. Jusko,et al. Pharmacokinetics in the infant. , 1994, Environmental health perspectives.
[110] E. Wirrell,et al. Specific safety and tolerability considerations in the use of anticonvulsant medications in children , 2012, Drug, healthcare and patient safety.
[111] A. Iolascon,et al. Challenges in prescribing drugs for children with cancer. , 2008, The Lancet. Oncology.
[112] E. Fuseau,et al. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[113] B. Friis‐Hansen. WATER DISTRIBUTION IN THE FOETUS AND NEWBORN INFANT , 1983, Acta paediatrica Scandinavica. Supplement.
[114] M. Morais,et al. Gastroesophageal reflux disease: exaggerations, evidence and clinical practice. , 2014, Jornal de pediatria.
[115] J. Rowe,et al. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. , 2008, Current drug safety.
[116] I. Kanfer,et al. Steady State Pharmacokinetics and Dose‐Proportionality of Phenylpropanolamine in Healthy Subjects , 1990, Journal of clinical pharmacology.
[117] J. Lantos,et al. Ethical issues in neonatal and pediatric clinical trials. , 2012, Pediatric clinics of North America.
[118] Hidefumi Nakamura,et al. Pharmacokinetics of the H2 Blocker Roxatidine Acetate Hydrochloride in Pediatric Patients, in Comparison with Healthy Adult Volunteers , 2012 .
[119] Gordon L. Amidon,et al. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.
[120] M. Strolin Benedetti,et al. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations , 2005, Expert opinion on drug metabolism & toxicology.
[121] D. Faulds,et al. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.
[122] S. Laurberg,et al. Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system , 2011, BMC gastroenterology.
[123] G. Koren. Therapeutic drug monitoring principles in the neonate , 1997 .
[124] E. Perucca,et al. Topiramate Pharmacokinetics in Children and Adults with Epilepsy , 2005, Clinical pharmacokinetics.
[125] T. Mayer,et al. Concentrations of Stiripentol in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication , 2012, Therapeutic drug monitoring.
[126] Vinita B Pai,et al. Nelfinavir Mesylate: A Protease Inhibitor , 1999, The Annals of pharmacotherapy.
[127] A. Dahan,et al. Regional-Dependent Intestinal Permeability and BCS Classification: Elucidation of pH-Related Complexity in Rats Using Pseudoephedrine , 2013, The AAPS Journal.
[128] A. Dahan,et al. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. , 2012, Molecular pharmaceutics.
[129] W. Garnett. Clinical Pharmacology of Topiramate: A Review , 2000, Epilepsia.
[130] T. Andersson,et al. Pharmacokinetics of orally administered omeprazole in children , 2000, American Journal of Gastroenterology.
[131] Jason Gerson,et al. Ethical considerations in conducting pediatric research. , 2011, Handbook of experimental pharmacology.
[132] A. Atkinson,et al. Principles of Clinical Pharmacology , 2001 .
[133] G. Salvia,et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[134] K. Simons,et al. Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. , 1996, The Journal of pediatrics.
[135] E. Palumbo. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. , 2008, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.